Group 1 - The World Data Organization (WDO) was established on March 30 in Beijing, aiming to bridge the data gap, unlock data value, and promote the digital economy [3] - The State Administration for Market Regulation issued a notice to combat "involution" competition in key industries such as platform economy, photovoltaic, lithium batteries, and new energy vehicles [3] - The Ministry of Commerce announced measures to boost consumption, including optimizing the trade-in policy for consumer goods and promoting the efficient circulation of second-hand cars [4] Group 2 - Hangzhou introduced a new housing provident fund policy, increasing the maximum loan amount for ordinary families to 1.8 million yuan, with potential increases for specific groups [4] - An international team, including researchers from Sweden's Karolinska Institute, developed a new method for generating CAR-T cells for cancer immunotherapy, with results published in the journal Nature [5] - U.S. President Trump indicated serious negotiations with Iran regarding military actions, while also threatening to destroy Iranian infrastructure if agreements are not reached [6] Group 3 - The Iranian parliament approved a bill to charge fees for ships passing through the Strait of Hormuz, which includes prohibiting vessels from the U.S. and Israel [9] - The U.S. Secretary of State stated that Iran must not be allowed to permanently control the Strait of Hormuz or establish a fee system [8] - U.S. stock indices showed mixed results, with the Dow Jones up 0.11% and the Nasdaq down 0.73%, while oil prices reached their highest level since July 2022 at $102.88 per barrel [7] Group 4 - Midea Group plans to repurchase shares worth between 6.5 billion and 13 billion yuan, with a projected net profit growth of 14.03% for 2025 [9] - SF Holding announced a plan to use up to 38 billion yuan for financial products and adjusted its share repurchase amount to between 3 billion and 6 billion yuan [9] - Zhongji Xuchuang expects a net profit growth of 108.78% for 2025 and plans to distribute 10 yuan per 10 shares [10]

Core Viewpoint - The article discusses a novel strategy for in vivo generation of CAR-myeloid cells through erythrocyte-mediated mRNA delivery, which shows promise for cancer immunotherapy [3][14]. Group 1: Research Background and Significance - CAR-myeloid cell therapy has potential in cancer immunotherapy, but clinical translation is hindered by low gene modification efficiency and complex production requirements [2]. - Traditional lipid nanoparticle (LNP) delivery methods face limitations such as accumulation in the liver and low escape efficiency from endosomes, which restrict their clinical applicability [2][4]. Group 2: Innovative Approach - The research team developed a method to covalently couple mRNA-LNP to the surface of red blood cells, leveraging their natural homing ability to the spleen for efficient targeting of myeloid cells [3][4]. - This strategy enhances mRNA release efficiency and therapeutic effects by utilizing physiological pathways rather than relying on passive distribution [4]. Group 3: Mechanism and Efficacy - The mRNA-LNP-Ery platform allows for selective and efficient delivery of mRNA to CD11b+ myeloid cells in the spleen, avoiding liver uptake [11]. - The study demonstrated that CAR-myeloid cells generated in vivo could migrate to tumors, eliminate cancer cells, and reshape the tumor microenvironment, leading to significant anti-tumor effects and prolonged survival [11][13]. Group 4: Clinical Implications - The findings suggest that the erythrocyte-mediated mRNA delivery platform could accelerate the clinical translation of CAR-myeloid cell therapies, building on previous research involving red blood cell-drug conjugates [4][14]. - The research indicates that the therapeutic activity of mRNA-LNP-Ery is dependent on the formation of CAR-myeloid cells in the spleen and their interaction with the adaptive immune system [13].

Core Viewpoint - The article discusses the advancements in CAR-T cell therapy for blood cancers and highlights the limitations of this therapy in treating solid tumors, emphasizing the potential of invariant Natural Killer T (iNKT) cells in cancer immunotherapy [3]. Group 1: iNKT Cells and CAR-iNKT Therapy - iNKT cells are a unique subset of T lymphocytes with allogeneic potential and strong homing ability to solid tumors, making them attractive for cancer immunotherapy [3]. - CAR-redirected iNKT (CAR-iNKT) cells have shown promise in anti-tumor applications, but their clinical efficacy is limited by insufficient activation in vivo and poor long-term survival in the tumor microenvironment [3]. Group 2: iMRAS Development - A research team from UCLA developed a biomimetic platform called iMRAS (iNKT cell-targeted Microparticle Recruitment and Activation System) that acts as an in vivo charging station to enhance the therapeutic effects of CAR-iNKT cells [4][6]. - The iMRAS platform consists of alginate microspheres embedded with nanoparticles that release immune-stimulating molecules, designed to recruit and activate CAR-iNKT cells in vivo, promoting their expansion and persistence [6]. Group 3: Mechanism and Impact - iMRAS provides chemotactic and activation signals, including a CD1d-αGC complex to simulate antigen presentation and an IL-15/IL-15Rα complex to enhance CAR-iNKT cell proliferation and longevity [6]. - The study indicates that iMRAS significantly improves the persistence and tumor-suppressive capabilities of CAR-iNKT cells in preclinical models of lymphoma and melanoma [6][8].

Core Viewpoint - The article discusses a novel approach in mRNA-based cancer immunotherapy, focusing on the use of prodrug ionizable lipid nanoparticles (pLNP) to enhance T cell activation while preventing T cell exhaustion, thereby improving anti-tumor responses [2][3][6]. Group 1: Research Overview - A research team from the University of Pennsylvania developed pLNP that combines an IDO inhibitor and IL-12 mRNA, achieving a synergistic effect in cancer treatment [3][8]. - The pLNP serves as both a drug and a delivery vehicle, where the ionizable lipid itself acts as a prodrug, releasing the IDO inhibitor upon cellular entry to inhibit T cell exhaustion [6][8]. Group 2: Mechanism of Action - The pLNP facilitates dual action: it activates T cells by delivering IL-12 mRNA and prevents their exhaustion by releasing the IDO inhibitor, effectively acting as both a "gas pedal" and a "brake release" in the tumor microenvironment [6][8]. - This coordinated action leads to increased T cell infiltration and reduced exhaustion in a mouse model of colon cancer, resulting in complete regression of primary tumors and activation of systemic immune responses [8]. Group 3: Implications for Cancer Immunotherapy - The integration of small molecule drugs and mRNA therapies within a single lipid nanoparticle represents a significant advancement in cancer immunotherapy, providing a powerful and innovative platform for treatment [3][8].

Core Viewpoint - The research identifies CLEC12B as an inhibitory checkpoint in NK cells, which limits their anti-tumor immune response, and proposes a novel therapeutic strategy targeting this pathway to enhance cancer immunotherapy [2][4]. Group 1: Research Findings - The study published in Nature Immunology reveals that high expression of CLEC12B in tumor-infiltrating NK cells of liver cancer patients correlates with poor clinical prognosis [4]. - The research team discovered that lipoprotein lipase acts as a functional ligand for CLEC12B, triggering inhibitory signaling that suppresses NK cell activation [4]. - A high-affinity nanobody was developed to disrupt the CLEC12B-lipoprotein lipase signaling axis, restoring NK cell activity and inhibiting tumor progression in preclinical models [4]. Group 2: Therapeutic Implications - The nanobody shows strong synergistic efficacy when used in combination with PD-1 blockade, establishing CLEC12B as a promising therapeutic target for rearming the immune system against solid malignancies [4].

Core Viewpoint - Targeting the gut microbiome is considered a promising strategy to enhance the efficacy of cancer immunotherapy, with fecal microbiota transplantation (FMT) showing limited success in clinical studies [3] Group 1: Research Findings - A study published in Nature Microbiology identified a specific microbial consortium, named RCom, derived from clinical responders of non-small cell lung cancer (NSCLC) patients, which enhances the efficacy of anti-PD-1 immunotherapy in mice [3][6] - The research team utilized metagenomic analysis and computational predictions to determine bacterial species associated with immune therapy responses in NSCLC patients, constructing a defined consortium of 15 bacterial species [6] Group 2: Characteristics and Effects of RCom - RCom is characterized as a stable and cooperative microbial community, capable of colonizing the intestines of mice and producing immunomodulatory metabolites [8] - In mouse models, oral administration of RCom significantly improved anti-tumor effects of anti-PD-1 therapy by enhancing the infiltration and cytotoxic function of CD8+ T cells within tumors, demonstrating effectiveness across different baseline gut microbiome compositions [8] - RCom also has the potential to overcome resistance to treatment, as it can limit the therapeutic resistance conferred by fecal microbiota from non-responding patients [8]

Core Viewpoint - Oncolytic viruses (OV) represent a promising therapy in cancer treatment, particularly for glioblastoma, by selectively replicating in tumor cells and activating immune responses [2][3][5]. Group 1: Clinical Trial Findings - A first-in-human phase 1 clinical trial reported safety data for 41 patients with recurrent glioblastoma (rGBM) treated with a modified oncolytic herpes simplex virus (oHSV), which selectively replicates in glioblastoma cells without harming healthy brain tissue [3]. - The treatment led to enhanced anti-cancer immune responses, with patient survival correlating with immune activation characteristics [3][4]. - Single oncolytic virus treatment resulted in deep and persistent T cell infiltration in glioblastoma, activating T cell-mediated cytotoxic responses associated with longer progression-free survival and overall survival [4][5]. Group 2: Immune Response Mechanisms - The study revealed that a single injection of oncolytic virus could transform the immune cold environment of glioblastoma into a hot environment rich in activated cytotoxic T cells, significantly extending patient survival [5]. - Evidence of early T cell activation and tissue residency was observed, with T cells near tumor cells expressing high levels of activation markers, indicating ongoing recognition of tumor antigens [8]. - The expansion of pre-existing tumor-infiltrating T cell clones was noted, correlating with longer overall survival, suggesting that the treatment amplifies existing immune responses [11]. Group 3: Treatment Challenges and Considerations - Despite strong T cell responses, hypoxic tumor regions exhibited T cell exclusion, potentially due to a suppressive microenvironment, which may contribute to treatment resistance [13]. - Long-term use of dexamethasone, a common medication for brain edema, was associated with reduced T cell clonality post-treatment, indicating a need for careful management of corticosteroids to optimize immune responses [14]. - The study emphasizes the importance of combining oncolytic virus therapy with agents that enhance T cell expansion and persistence, as well as anti-VEGF therapies to overcome hypoxic conditions [17].

Core Viewpoint - The article discusses the discovery of a new immune checkpoint, SLAMF6, which plays a crucial role in T cell-mediated anti-tumor immunity and presents a potential new target for cancer immunotherapy, complementing or even replacing existing PD-1/PD-L1 inhibitors [3][12][17]. Group 1: Limitations of Traditional Immunotherapy - Current PD-1/PD-L1 inhibitors work by blocking the interaction between PD-1 on T cells and PD-L1 on tumor cells, but not all tumors express PD-L1, and some patients develop resistance over time [6][5]. - There is a pressing need to identify new immune checkpoints to benefit a broader range of cancer patients [3]. Group 2: Disruptive Discovery of SLAMF6 - SLAMF6 is identified as a key suppressor of T cell immunity against cancer, functioning through a unique mechanism called "cis-interaction," where SLAMF6 molecules on the same T cell surface interact to exert a "self-inhibition" effect [3][11]. - Research shows that T cells lacking SLAMF6 exhibit stronger activation and anti-tumor effects, regardless of whether tumor cells express SLAMF6 [9][11]. Group 3: From Laboratory to Clinical Application - The research team developed monoclonal antibodies that effectively block human SLAMF6, significantly enhancing T cell activation and reducing exhausted T cell proportions in various mouse tumor models, outperforming PD-L1 inhibitors [13][15]. - The combination of SLAMF6 antibodies with PD-L1 inhibitors shows synergistic effects, suggesting new avenues for combination therapies [15]. Group 4: Safety and Future Prospects - No severe side effects, such as cytokine storms, were observed with SLAMF6 antibody treatment, providing a solid foundation for clinical development [17]. - Future steps include optimizing antibody design, potentially developing bispecific antibodies to target T cells in the tumor microenvironment more specifically [17].

Core Viewpoint - The article discusses the inherent randomness in cancer immunotherapy responses, highlighting the discovery of a rare but critical T cell subset known as Spark T cells, which significantly influences treatment outcomes [2][4]. Group 1: Randomness in Cancer Immunotherapy - Cancer immunotherapy has shown success in a small subset of patients who do not respond to traditional therapies, but many patients still do not respond well due to various factors [2]. - The effectiveness of immunotherapy varies greatly among patients with similar conditions, indicating an intrinsic randomness in treatment outcomes [2][7]. - A study demonstrated that even under identical experimental conditions, the results of immunotherapy can differ significantly, with some cancer cells being completely eradicated while others remain unaffected [7]. Group 2: Discovery of Spark T Cells - The research identified Spark T cells, a rare T cell subset that plays a crucial role in the effectiveness of cancer immunotherapy, comprising only 1 in 2500 to 1 in 1000 of all T cells [9]. - Spark T cells can rapidly produce large amounts of interferon-gamma (IFN-γ) upon recognizing cancer cells, initiating a positive feedback loop that activates more T cells for a robust immune response [9][10]. - The unique characteristics of Spark T cells, including their epigenetic features that allow quick responses to antigen signals, contribute to their high efficiency in targeting tumors [10]. Group 3: Clinical Implications and Future Directions - The identification of Spark T cells may lead to new biomarkers for predicting the efficacy of immunotherapy, allowing for better patient selection and reducing unnecessary side effects and costs [13]. - Enriching or expanding Spark T cells could represent a new direction for cell therapies, potentially enhancing the effectiveness of adoptive T cell therapies [13]. - This research provides a new framework for understanding the variability in immunotherapy responses, with the potential to make treatment outcomes more predictable and effective [13].

Core Viewpoint - The recent study published in Cell journal explores the potential of sensitized mast cells as a targeted drug delivery system for cancer immunotherapy, redirecting the immune response typically associated with allergies to combat cancer [3][4][12]. Group 1: Research Overview - The study introduces an engineered mast cell platform that utilizes tumor-associated antigens as "allergens" to drive the accumulation of mast cells loaded with anti-tumor drugs, such as oncolytic viruses, to tumor sites [4][10]. - The research team developed an antigen-guided mast cell-mediated drug delivery system, demonstrating the innovative design through a cover image that symbolizes the interaction between antigens and mast cells [7]. Group 2: Mechanism and Findings - The study focuses on immunoglobulin E (IgE) sensitized mast cells (IgE-MC) for targeted delivery of oncolytic adenoviruses and local immune activation, showing significant potential in enhancing cancer treatment efficacy [8][10]. - IgE-MC can selectively target antigen-positive tumors, releasing oncolytic viruses and cytokines/chemokines upon antigen binding, thereby reversing immune suppression and activating anti-tumor immune responses [10][12]. Group 3: Safety and Efficacy - The infusion of IgE-MC is cleared within two weeks without disrupting mast cell homeostasis or inducing systemic allergic reactions, demonstrating a favorable safety profile [9]. - Compared to free oncolytic viruses, IgE-MC delivered oncolytic viruses showed reduced liver toxicity and no viral replication detected in normal tissues, indicating a safer therapeutic approach [9].